Tailoring DNA vaccines: Designing strategies against HER2-positive cancers

Frontiers in Oncology

Volumn 3 MAY, Issue , 2013, Pages

  Marchini, Cristina ^a   Kalogris, Cristina ^a   Garulli, Chiara ^a   Pietrella, Lucia ^a   Gabrielli, Federico ^a   Curcio, Claudia ^b   Quaglino, Elena ^c   Cavallo, Federica ^c   Amici, Augusto ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Breast cancer; DNA vaccines; HER2; Immunological tolerance; Immunotherapy

Indexed keywords

DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 2; KANAMYCIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CELLULAR IMMUNITY; DENDRITIC CELL; GENETIC TRANSCRIPTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; NEOPLASM; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); RECOMBINANT DNA TECHNOLOGY;

EID: 84888313531     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00122     Document Type: Article

References (34)

1. Ambrosino, E., Spadaro, M., Iezzi, M., Curcio, C., Forni, G., Musiani, P., et al. (2006). Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res. 66, 7734-7740.
2. Amici, A., Smorlesi, A., Noce, G., Santoni, G., Cappelletti, P., Capparuccia, L., et al. (2000). DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Gene Ther. 7, 703-706.
3. Bodles-Brakhop, A. M., Heller, R., and Draghia-Akli, R. (2009). Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol. Ther. 17, 585-592.
4. Brummelkamp, T. R., Bernards, R., and Agami, R. (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550-553.
5. Cavallo, F., De Giovanni, C., Nanni, P., Forni, G., and Lollini, P. L. (2011). 2011: the immune hallmarks of cancer. Cancer Immunol. Immunother. 60, 319-326.
6. Cho, H. S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W. Jr., et al. (2003). Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421, 756-760.
7. Curcio, C., Di Carlo, E., Clynes, R., Smyth, M. J., Boggio, K., Quaglino, E., et al. (2003). Nonredundant roles of antibody, cytokines and perforin in the eradication of established Her-2/neu carcinomas. J. Clin. Invest. 111, 1161-1170.
8. Finn, O. J. (2003). Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3, 630-641.
9. Fynan, E. F., Webster, R. G., Fuller, D. H., Haynes, J., Santoro, J. C., and Robinson, H. L. (1993). DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. U.S.A. 90, 11478-11482.
10. Gabrielli, F., Salvi, R., Garulli, C., Kalogris, C., Arima, S., Tardella, L., et al. (2013). Identification of relevant conformational epitopes on the HER2 oncoprotein by using Large Fragment Phage Display (LFPD). PLoS ONE 8:e58358. doi:10.1371/journal.pone.0058358
11. Hart, D. N. (1997). Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90, 3245-3287.
12. Jacob, J. B., Quaglino, E., Radkevich-Brown, O., Jones, R. F., Piechocki, M. P., Reyes, J. D., et al. (2010). Combining human and rat sequences in HER-2 DNA vaccines blunts immune tolerance and drives antitumor immunity. Cancer Res. 70, 119-128.
13. Jarnicki, A. G., Lysaght, J., Todryk, S., and Mills, K. H. (2006). Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor enviroment on the induction of CD4+ and CD8+ regulatory T cells. J. Immunol. 177, 896-904.
14. Krieg, A. M. (2002). CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760.
15. Ladjemi, M. Z., Jacot, W., Chardès, T., Pèlegrin, A., and Navarro-Teulon, I. (2010). Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol. Immunother. 59, 1295-1312.
16. Liu, M. A. (2003). DNA vaccines: a review. J. Intern. Med. 253, 402-410.
17. Lollini, P. L., Cavallo, F., Nanni, P., and Forni, G. (2006). Vaccines for tumour prevention. Nat. Rev. Cancer 6, 204-216.
18. Lollini, P. L., and Forni, G. (2003). Cancer immunoprevention: tracking down persistent tumor antigens. Trends Immunol. 24, 62-66.
19. Nguyen-Hoai, T., Baldenhofer, G., Sayed Ahmed, M. S., Pham-Duc, M., Vu, M. D., Lipp, M., et al. (2012). CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model. Cancer Gene Ther. 19, 69-76.
20. Norell, H., Poschke, I., Charo, J., Wei, W. Z., Erskine, C., Piechocki, M. P., et al. (2010). Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J. Transl. Med. 8, 53-63.
21. Quaglino, E., Iezzi, M., Mastini, C., Amici, A., Pericle, F., Di Carlo, E., et al. (2004). Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res. 64, 2858-2864.
22. Quaglino, E., Mastini, C., Amici, A., Marchini, C., Iezzi, M., Lanzardo, S., et al. (2010). A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res. 70, 2604-2612.
23. Quaglino, E., Mastini, C., Forni, G., and Cavallo, F. (2008). ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas. Curr. Protoc. Immunol. 20, 20.9.1-20.9.10.
24. Quaglino, E., Mastini, C., Iezzi, M., Forni, G., Musiani, P., Klapper, L. N., et al. (2005). The adjuvant activity of BAT antibody enables DNA vaccination toinhibit the progression of established autochthonous Her-2/neucarcinomas in BALB/c mice. Vaccine 23, 3280-3287.
25. Quaglino, E., Riccardo, F., Macagno, M., Bandini, S., Cojoca, R., Ercole, E., et al. (2011). Chimeric DNA vaccines against ErbB2+ carcinomas: from mice to humans. Cancers 3, 3225-3241.
26. Rolla, S., Marchini, C., Malinarich, S., Quaglino, E., Lanzardo, S., Montani, M., et al. (2008). Protective immunity against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing fragments of rat neu extracellular domain. Hum. Gene Ther. 19, 229-239.
27. Rolla, S., Nicoló, C., Malinarich, S., Orsini, M., Forni, G., Cavallo, F., et al. (2006). Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J. Immunol. 177, 7626-7633.
28. Rolla, S., Ria, F., Occhipinti, S., Di Sante, G., Iezzi, M., Spadaro, M., et al. (2010). Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy. J. Immunol. 184, 6124-6132.
29. Rovero, S., Amici, A., Di Carlo, E., Bei, R., Nanni, P., Quaglino, E., et al. (2000). DNA Vaccination against rat Her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol. 165, 5133-5142.
30. Steinman, R. M., and Inaba, K. (1999). Myeloid dendritic cells. J. Leukoc. Biol. 66, 205-208.
31. Stoitzner, P., Green, L., Jung, J., Price, K., Atarea, H., Kivell, B., et al. (2008). Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunol. Immunother. 57, 1665-1673.
32. Ursini-Siegel, J., Schade, B., Cardiff, R. D., and Muller, W. J. (2007). Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat. Rev. Cancer 7, 389-397.
33. von Bergwelt-Baildon, M. S., Popov, A., Saric, T., Chemnitz, J., Classen, S., Stoffel, M. S., et al. (2006). CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108, 228-237.
34. Yen, M. C., Lin, C. C., Chen, Y. L., Huang, S. S., Yang, H. J., Chang, C. P., et al. (2009). A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. Clin. Cancer Res. 15, 641-649.